SEARCH

SEARCH BY CITATION

References

  • Avitabile D, Bailey B, Cottage CT, Sundararaman B, Joyo A, McGregor M, Gude N, Truffa S, Zarrabi A, Konstandin M, et al (2011) Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin. Proc Natl Acad Sci 108: 61456150
  • Battiprolu PK, Hojayev B, Jiang N, Wang ZV, Luo X, Iglewski M, Shelton JM, Gerard RD, Rothermel BA, Gillette TG, et al (2012) Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 122: 11091118
  • Birse RT, Choi J, Reardon K, Rodriguez J, Graham S, Diop S, Ocorr K, Bodmer R, Oldham S (2010) High-fat-diet-induced obesity and heart dysfunction are regulated by the TOR pathway in Drosophila. Cell Metab 12: 533544
  • Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115: 32133223
  • Chen C, Liu Y, Liu R, Ikenoue T, Guan K-L, Liu Y, Zheng P (2008) TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 205: 23972408
  • Cheng Z, Völkers M, Din S, Avitabile D, Khan M, Gude N, Mohsin S, Bo T, Truffa S, Alvarez R, et al (2011) Mitochondrial translocation of Nur77 mediates cardiomyocyte apoptosis. Eur Heart J 32: 21792188
  • Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171183
  • Fang Y, Westbrook R, Hill C, Boparai RK, Arum O, Spong A, Wang F, Javors MA, Chen J, Sun LY, et al (2013) Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab 17: 456462
  • Gan B, Sahin E, Jiang S, Sanchez-Aguilera A, Scott KL, Chin L, Williams DA, Kwiatkowski DJ, Depinho RA (2008) mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci 105: 1938419389
  • Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, et al (2013) Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127: 143152
  • Goldberg IJ, Trent CM, Schulze PC (2012) Lipid metabolism and toxicity in the heart. Cell Metab 15: 805812
  • Howell JJ, Manning BD (2011) mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab 22: 94102
  • Kim JE, Chen J (2004) Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53: 27482756
  • Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, Roth RA (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278: 1018910194
  • Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149: 274293
  • Most P, Pleger ST, Völkers M, Heidt B, Boerries M, Weichenhan D, Löffler E, Janssen PML, Eckhart AD, Martini J, et al (2004) Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 114: 15501563
  • Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, Esposito G, Delucchi F, Arcarese M, Alvarez R, et al (2007) Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 14671475
  • Oshiro N, Takahashi R, Yoshino K-I, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, et al (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282: 2032920339
  • Quijada P, Toko H, Fischer KM, Bailey B, Reilly P, Hunt KD, Gude NA, Avitabile D, Sussman MA (2012) Preservation of myocardial structure is enhanced by Pim-1 engineering of bone marrow cells. Circ Res 111: 7786
  • Rachdi L, Aïello V, Duvillié B, Scharfmann R (2012) l-Leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes 61: 409417
  • Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903915
  • Stallone G, Infante B, Grandaliano G, Gesualdo L (2009) Management of side effects of sirolimus therapy. Transplantation 87: S23S26
  • Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316323
  • Völkers M, Weidenhammer C, Herzog N, Qiu G, Spaich K, von Wegner F, Peppel K, Müller OJ, Schinkel S, Rabinowitz JE, et al (2011) The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition. Circ Res 108: 2739
  • Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471484